Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NK cell therapy for cancer
NL-OMON61483Not yet recruiting
- Sponsor
- Maastricht University
- Start
- Sep 2026
- Countries
- 1
01
Overview
Open-label, single-arm trial of Natural Killer Cells in breast cancer, pancreatic cancer (PC), multiple myeloma (MM) and 3 more, sponsored by Maastricht University. Primary endpoints: Functional characteristics of NK cells, Phenotypic characteristics of NK cells and 1 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
Natural Killer Cells
03
Conditions
breast cancerpancreatic cancer (PC)multiple myeloma (MM)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NL-OMON61483.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61483.